Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials

Bibliographische Detailangaben
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
von: Enrica Antonia Martino, et al.
Veröffentlicht: (2025)

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
von: Michèle Hoffmann, et al.
Veröffentlicht: (2025)

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
von: Iuliana Vaxman, et al.
Veröffentlicht: (2026)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
von: J.T. Jutzi, et al.
Veröffentlicht: (2025)

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
von: Lucio N. Gordan, et al.
Veröffentlicht: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
von: Dong Liang, et al.
Veröffentlicht: (2025)

Therapy Sequencing in Relapsed/Refractory MCL
von: Eva Giné
Veröffentlicht: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
von: Yoshikazu Ikoma, et al.
Veröffentlicht: (2025)

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation
von: Nathalie Javidi‐Sharifi, et al.
Veröffentlicht: (2025)

Multiple Myeloma Unpacked
von: Francesca Gay, et al.
Veröffentlicht: (2025)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
von: Giacomo Loseto, et al.
Veröffentlicht: (2025)

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study
von: Ben Varon, et al.
Veröffentlicht: (2026)

Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
von: Idanna Innocenti, et al.
Veröffentlicht: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
von: Jinyan Xiao, et al.
Veröffentlicht: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
von: Meirav Kedmi, et al.
Veröffentlicht: (2024)

Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period
von: Xue Yang, et al.
Veröffentlicht: (2025)

Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
von: Doriana Gramegna, et al.
Veröffentlicht: (2026)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
von: Inna Y. Gong, et al.
Veröffentlicht: (2026)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
von: Pier Luigi Zinzani, et al.
Veröffentlicht: (2025)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
von: Jiajie He, et al.
Veröffentlicht: (2026)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
von: Masahito Tokunaga, et al.
Veröffentlicht: (2025)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
von: Fenghua Gao, et al.
Veröffentlicht: (2025)

Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
von: Tom Schlusemann, et al.
Veröffentlicht: (2026)

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
von: Ernesto Vigna, et al.
Veröffentlicht: (2025)

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
von: Calogero Vetro, et al.
Veröffentlicht: (2026)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
von: Juan Quarroz Braghini, et al.
Veröffentlicht: (2025)

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
von: Zhiqiang Song, et al.
Veröffentlicht: (2026)

Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
von: Koji Kawamura, et al.
Veröffentlicht: (2025)

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
von: Jana Gregorova, et al.
Veröffentlicht: (2025)

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
von: Francesco Passamonti, et al.
Veröffentlicht: (2026)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
von: Francesca Maria Quaglia, et al.
Veröffentlicht: (2026)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
von: Hala Bekhit, et al.
Veröffentlicht: (2025)

Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
von: Prokop Vodicka, et al.
Veröffentlicht: (2025)

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
von: M. Delia, et al.
Veröffentlicht: (2025)

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience
von: Idanna Innocenti, et al.
Veröffentlicht: (2024)

Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients
von: Tatsuzo Mishina, et al.
Veröffentlicht: (2025)

Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
von: M. Picardi, et al.
Veröffentlicht: (2024)

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation
von: Francesco Autore, et al.
Veröffentlicht: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
von: Minna Harmanen, et al.
Veröffentlicht: (2025)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
von: Pallawi Torka, et al.
Veröffentlicht: (2025)

Ähnliche Einträge

Ähnliche Einträge